abstract:acute venous thromboembolism (vte) is a common disease associated with the significant morbidity and mortality. we reviewed clinical outcomes systematically with dabigatran as a direct oral anticoagulants (doac) for treatment of acute vte. we used ovide, pubmed, cochrane (central), embase, scopus, science direct, lilac(for article written not english) and also iranian database; magiran...

Although anticoagulants have been in use for more than 80 years, heparin and vitamin K antagonists were the sole available options until recently. these agents revolutionized prevention treatment of thrombotic diseases, their has hampered by necessity coagulation monitoring bleeding complications resulting part from multiple sites action. Owing to advances basic science, animal models, epidemio...

Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a major concern in clinical practice. After DOACs were introduced and became widely used as an alternative for vitamin K antagonists in the management of venous thromboembolism and nonvalvular atrial fibrillation, the need for effective reversal agents has increased, particu...

Introduction Novel oral anticoagulants (NOACs) represents a group of medications: direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) are increasingly favorized over conventional oral anticoagulants (OAC), vitamin K oral anticoagulants such as warfarin. As requested by some authors the term “NOACs”, should be restricted to “non-vitamin K o...